Drugmaker GSK Plc said on Wednesday that Q2 revenues had grown as a strong specialty medicines performance drove sales and core operating profit growth.
GSK said Q2 revenues were 5% at £8.1bn, buoyed by its vaccines and specialty medicines divisions, while operating profits climbed 12% to £2.1bn, and adjusted earnings per share rose 7% to 41.8p.
Vaccines led the charge, jumping 15% on the back of demand for its shingles jab, Shingrix, and RSV vaccine, Arexvy. Specialty medicines followed suit, posting a 12% rise, with solid growth in HIV treatments and oncology assets. General medicines, however, slipped 2% due to pricing pressures and competitive headwinds.
Looking ahead, GSK reaffirmed its FY guidance, targeting 5%-7% sales growth and 6-9% EPS growth at constant exchange rates.
Chief executive Emma Walmsley said: "GSK's strong momentum in 2025 continues with another quarter of excellent performance driven mainly by specialty medicines, our largest business, with double-digit sales growth in respiratory, immunology & inflammation, oncology and HIV.
"We now expect to be towards the top end of our financial guidance for 2025 and remain confident in our long-term outlooks."
Reporting by Iain Gilbert at Sharecast.com